Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Contract Type
licensing
Description
On October 13, 2026, Ocugen, Inc. entered into an Exclusive License Agreement with Roots Pharmaceutical Company, granting Roots rights to develop and commercialize OCU400 in the Middle East and North Africa. The agreement includes an upfront license fee, regulatory and milestone payments of up to $4 million, and sales milestone payments potentially totaling $255 million. Additionally, Ocugen will receive a 22% royalty on net sales of the licensed product in the Territory.
Ocugen signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.